Evidence map›Paper›PMID 36012769›Full record

ArticleInternational journal of molecular sciences2022

Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells.

Gulcin Tezcan, Mohammad Alsaadi, Shaimaa Hamza, Ekaterina E Garanina, Ekaterina V Martynova, Gulshat R Ziganshina, Elina R Farukshina, Albert A Rizvanov, Svetlana F Khaiboullina

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Gulcin TezcanInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-5956-8755
Mohammad AlsaadiInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Shaimaa HamzaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-5012-4760
Ekaterina E GaraninaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Ekaterina V MartynovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Gulshat R ZiganshinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Elina R FarukshinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Albert A RizvanovInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9427-5739
Svetlana F KhaiboullinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Kazan Federal University · RUBursa Uludağ Üni̇versi̇tesi̇ · TR

Funding

Kazan Federal University Strategic Academic Leadership Program PRIORITY-2030Russian President's grant #МК-3571.2021.1.4
6 · The paper itself

Abstract

backgroundCancer patients are prescribed antibiotics, such as macrolides and lactamides, for infection treatment. However, the effect of these antibiotics on NLRP3 activation remains largely unknown.

methodLung cancer (A549) and prostate cancer (PC3) cell lines were primed with lipopolysaccharide (LPS) to activate NLRP3 transcription. Cells were then treated with azithromycin (Az) or ceftriaxone (Cf). NLRP3 activation was analyzed by qPCR, Western blot, and ELISA. Cell growth and viability were assessed by real-time cell analysis and Annexin V expression. Levels of 41 cytokines were also analyzed using a multiplex assay.

resultsLPS-Az activated transcription of DISCUSSION: Our data suggest that Cf could suppress LPS induced NLRP3, which should be considered when selecting antibiotics for cancer treatment. In contrast, the effect of Az on LPS primed NLRP3 and the inflammatory cytokines production appears to depend on the cancer cell origin. Therefore, these data indicate that considerations are required when selecting Az for the treatment of cancer patients.

Indexed as

AzithromycinCeftriaxoneNeoplasmsNLR Family, Pyrin Domain-Containing 3 ProteinCell Line, TumorCytokinesHumansInflammasomesInterleukin-1betaLipopolysaccharidesAzithromycinCeftriaxoneCytokinesInflammasomesInterleukin-1betaLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanazithromycincancerceftriaxoneinflammasomeNod-like receptor protein 3 (NLRP3)

Identifiers

PMID36012769
PMCPMC9409354
OpenAlexW4292686623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.